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The biologically active form of Human 
Immunodeficiency Virus type 1 Reverse 
Transcriptase (RT) is a heterodimer. The 
formation of RT is a two-step mechanism, 
including a rapid protein/protein interaction 
“the dimerization step”, followed by 
conformational changes “the maturation step”, 
yielding the biologically active form of the 
enzyme. We have previously proposed that the 
heterodimeric organization of RT constitutes an 
interesting target for the design of new 
inhibitors. Here, we propose a new class of 
reverse transcriptase inhibitors that targets 
protein/protein interactions and conformational 
changes involved in the maturation of 
heterodimeric reverse transcriptase. Based on a 
screen of peptides derived from the thumb 
domain of this enzyme, we have identified a 
short peptide PAW that inhibits the maturation 
step and blocks viral replication at 
subnanomolar concentrations. PAW only binds 
dimeric RT and stabilizes it in an inactive/ non 
processive conformation. From a mechanistic 
point of view, PAW prevents proper binding of 
primer/template by affecting the structural 
dynamics of the thumb/fingers of p66 subunit. 
Taken together, these results demonstrate that 
HIV-1 RT maturation constitutes an attractive 
target for AIDS chemotherapeutics 
  
Human immunodeficiency virus type I (HIV-
1) is the primary cause of acquired 
immunodeficiency syndrome (AIDS), a slow 
progressive and degenerative disease of the human 
immune system. Despite recent therapeutic 
developments and the introduction of Highly 
Active Antiretroviral Therapy (HAART), the rapid 
emergence of drug-resistant viruses against all 
approved drugs together with inaccessible latent 
virus reservoirs and side effects of currently used 
compounds have limited the efficacy of existing 
anti-HIV-1 therapeutics (1).Therefore, there is still 
an urgent need for new and safer drugs, active 
against resistant viral strains or directed towards 
novel targets in the replicative cycle, which will be 
useful for multiple drug combination. 
HIV-1 reverse transcriptase (RT) plays an 
essential multifunctional role in the replication of 
the virus, by catalysing the synthesis of double-
stranded DNA from the single-strand retroviral 
RNA genome (2,3). The majority of the 
chemotherapeutic agents used in AIDS treatments 
target the polymerase activity of HIV-1 RT, such 
as nucleoside reverse transcriptase inhibitors 
(NRTI) or non-nucleoside inhibitors (NNRTI) (4). 
The biologically active form of RT is an 
asymmetric heterodimer that consists of two 
subunits, p66 and p51 derived from p66 by 
proteolytic cleavage of the C-terminal RNAse H 
domain (2,3,5).  
The polymerase domain of both p66 and p51 
subunit can be subdivided into four common 
subdomains: fingers, palm, thumb and connection 
(6-10). Determination of the three-dimensional 
structures of RTs has revealed that although the 
folding of individual subdomains is similar in p66 
and p51, their spatial arrangement differs markedly 
(11). The p66 subunit contains both polymerase 
and RNase H active sites. The p66-polymerase 
domain folds into an “open”, extended structure, 
forming a large active site cleft with the three 
catalytic residues (Asp110, Asp185, Asp186) within 
the palm subdomain exposed in the nucleic acid 
binding site. The primer grip is responsible for the 
appropriate placement of the primer terminus at the 
   
 2
polymerase active site and is involved in 
translocation of the primer-template (p/t) 
following nucleotide incorporation (12-14). In 
contrast, p51 predominantly plays a structural role 
in the RT heterodimer, by stabilizing the dimer 
interface thereby favouring loading of the p66 onto 
the p/t and maintaining the appropriate enzyme 
conformation during initiation of reverse 
transcription (15).  
In order to propose new classes of HIV 
inhibitors, extensive efforts have been made in the 
design of molecules that target protein/protein 
interfaces required for viral entry, replication and 
maturation (16-19). We (20,22) and others (5,24) 
have proposed that the heterodimeric organization 
of RT constitutes an interesting target for the 
design of new inhibitors. The formation of the 
active heterodimeric HIV-1 RT occurs in a two 
step process. First a rapid association of the two 
subunits (dimerization-step) via their connection 
sub-domains thereby yielding an inactive 
intermediate-RT, followed by a slow 
conformational change of this intermediate 
(maturation-step), generating the biologically 
active form of this enzyme. The maturation step 
involves contacts between the thumb of p51 and 
the RNAse H of p66 as well as between the fingers 
of p51 with the palm of p66 (20-23). NNRTIs 
have been reported to interfere with RT 
dimerization and to modulate the overall stability 
of the heterodimeric RT depending on their 
binding site on RT (24-28). NNRTIs including 
Efavirenz and Nevirapine have been shown to 
promote HIV-1 RT maturation at the level of the 
Gag-Pol protein and to affect viral protease (PR) 
activation, resulting in the suppression of viral 
release from infected cells (30,31). Conversely, 
NNRTIs such as TSAO and BBNH derivatives act 
as destabilizers of RT subunit interaction (27).   
 We have demonstrated that preventing or 
controlling RT dimerization constitutes an 
alternative strategy to block HIV proliferation and 
has a major impact on the viral cycle (32). In 
protein-protein interactions the binding energy is 
not evenly distributed across the dimer interface 
but involves specific residues “hot spots” that 
stabilize protein complexes. We have shown that 
the use of small peptides targeting “hot spot” 
residues required for RT-dimerization constitutes a 
new strategy to inhibit HIV-1 RT (16,17) and have 
described a decapeptide “Pep-7” mimicking 
p66/p51 interface that prevents RT-dimerization 
by destabilizing RT subunit-interactions and that 
blocks viral replication (23,32).   
The thumb domain plays an important role 
in the catalysis and integrity of the dimeric form of 
RT, thereby constituting a potential target for the 
design of novel antiviral compounds (7,8,22). The 
p66-thumb domain is involved in p/t binding and 
polymerase activity of RT (7,8,13) and p51-thumb 
domain is required for the conformational changes 
associated with RT dimer-maturation (22). We 
have designed a peptide, Pep-A, derived from a 
structural motif located between residues 284 and 
300, corresponding to the end of helix αI, the loop 
connecting helices αI and αJ and a part of helix αJ. 
This peptide is a potent inhibitor of RT interfering 
with the conformational change associated with 
full activation of the enzyme. However, although it 
significantly blocks RT maturation in vitro, it lacks 
of antiviral activity (22). In the present work, we 
have designed and evaluated a series of peptides 
derived from the thumb subdomain of RT using 
Pep-A as a template. We have identified a 17-
residue peptide PAW, which constitutes a potent 
inhibitor of RT-polymerase activity of HIV-1 RT 
in vitro. We have demonstrated that PAW inhibits 
RT maturation and abolishes viral replication 
without any toxic side-effects. The characterization 
of the mechanism through which PAW inhibits RT, 
combining steady-state and pre-steady state 
methods, together with size exclusion 
chromatography has revealed that PAW only binds 
dimeric-RT and stabilizes it in an inactive/non 
processive dimeric conformation that prevents the 
proper binding of p/t. Taken together, these results 
demonstrate that conformational flexibility of 
HIV-1 RT during maturation constitutes an 
attractive target for AIDS chemotherapeutics 
  
MATERIALS AND METHODS 
 
Materials - Poly(rA)-oligo(dT) and 3H-dTTP (1 
µCi/µl) were purchased from Amersham 
Biosciences (Orsay, France). dTTP was from 
Roche Molecular Biochemicals, Roche 
Diagnostics (Meylan, France). MF-membrane (25 
mm, 0.45 µm) filters for RT assay were purchased 
from Millipore (Molshein, France). Primer and 
template oligonucleotides were from MWG 
Biotech AG, (Ebersberg, Germany). A 19/36-mer 
DNA/DNA primer/template was used for steady-
state fluorescence titration and stopped-flow 
experiments, with 5’-
TCCCTGTTCGGGCGCCACT-3’ for the primer 
strand and 5’-
TGTGGAAAATCTCATGCAGTGGCGCCCGAA
CAGGGA-3’ for a template-strand. The sequence 
of the template strand corresponds to the sequence 
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of the natural primer binding site (PBS) of HIV-1 
(33). The primer was labelled at the 3’-end with 6-
carboxyfluorescein (6-FAM) on thymine base. 
Primer and template oligodeoxynucleotides were 
separately resuspended in water and diluted to 100 
μM in annealing buffer (25 mM Tris pH 7.5 and 
50 mM NaCl). Oligonucleotides were mixed 
together and heated at 95°C for 3 min, then cooled 
to room temperature for 1h.  
 
Expression and purification of HIV-1 RT 
proteins - His-tagged RTs were expressed and 
purified as previously described (23,34).  Briefly, 
M15 bacteria (Qiagen Courtaboeuf, France) were 
separately transformed with all the constructs of 
p51 and p66 subunits. Cells were grown at 37 °C 
up to about 0.3 OD595, then cultures were cooled to 
20°C and induced overnight with 0.5 mM 
isopropyl-1-thio-β-D-galactopyranoside. Bacterial 
cultures expressing His-tagged p66 subunit were 
mixed with cultures expressing His-tagged p51 
subunit to enable dimerization during sonication. 
For protein isolation and initial purification, the 
filtered supernatant was applied onto a Hi-Trap 
chelating column equilibrated with 50 mM sodium 
phosphate buffer, pH: 7.8, containing 150 mM 
NaCl supplemented with 50 mM imidazole. The 
heterodimeric p66/p51 RT was eluted with an 
imidazole gradient and finally purified by size-
exclusion chromatography on a HiLoad 16/60 
Superdex 75 column equilibrated with a 50 mM 
Tris pH: 7.0 buffer containing 1mM EDTA and 50 
mM NaCl. Recombinant untagged- HIV-1 BH10 
RT was expressed in E.coli and purified as 
previously described (35). Highly homogeneous 
preparations from co-expression of the p66 and 
p51 subunits were stored in -80°C in buffer 
supplemented with 50% glycerol. Protein 
concentrations were determined at 280 nm using a 
molar extinction coefficient of 260 450 M-1.cm-1.  
 
Peptide synthesis - Pep-A derived peptides were 
purchased from GL Biochem, (Shanghai, China) 
and Genepep, SA. (Prades le Lez, France). Pep-1 
and PAW were synthesized using an 
(fluorenylmethoxy)-carbonyl (Fmoc) continuous 
(Pionner, Applied Biosystems, Foster city, CA) 
starting from Fmoc-polyamide linker (PAL)-
poly(ethyleneglycol) (PEG)-polystyrene (PS) resin 
at a 0.05 mmol scale. Peptides were purified by 
semi-preparative reverse-phase high performance 
liquid chromatography (RP-HPLC; C18 column 
Interchrom UP5 WOD/25M Uptisphere 300 5 
ODB, 250 mm x 21.2 mm) and identified by 
electrospray mass spectrometry. PAW (1 mM) was 
coupled to FITC using maleimide-FITC 
(Molecular Probes. Inc.) (5 mM) through overnight 
incubation at 4°C in Phosphate Buffer Saline 
(PBS: GIBCO BRL). Fluorescently labelled 
peptide was further purified by RP-HPLC using a 
C18 reverse-phase HPLC column (Interchrom UP5 
HDO/25M Modulo-cart Uptisphere, 250 mm x 10 
mm) then identified by electrospray mass 
spectrometry.    
 
RT-polymerase Assay – RNA-dependent-DNA 
RT-polymerase activity was measured in a 
standard reaction assay using poly(rA)-(dT)15 as 
template/primer as previously described (5). 
Briefly, ten microliters of RT at 20 nM was 
incubated at 37 °C for 30 min with 20 µL of 
reaction buffer (50 mM Tris, pH 8.0, 80 mM KCl, 
6 mM MgCl2, 5 mM DTT, 0.15 µM poly(rA-dT), 
15 µM dTTP, 0.3 µCi 3H-dTTP). For peptide 
evaluation, HIV-1 RT was incubated with 
increasing concentrations of peptide inhibitors for 
23 hrs, and polymerase reaction was initiated by 
adding reaction buffer. Reactions were stopped by 
precipitation of nucleic acids with 5 ml of 20% 
trichloroacetic acid (TCA) solution for 2 h on ice, 
then filtered using a multiwell-sample collector 
(Millipore), and washed with 5% TCA solution. 
Filters were dried at 55°C for 30 min and 
radionucleotide incorporation was determined by 
liquid scintillation spectrometry. Data were fitted 
using a Dixon plot reporting the reciprocal of the 
velocity (1/v) as a function of inhibitor 
concentrations. Ki values for the different peptides 
were estimated from the intercept on the 
concentration axis (36).   
 
Steady-State Fluorescence Experiments - 
Fluorescence experiments were performed in 
buffer containing 50 mM Tris-HCl, pH 8.0, 50 mM 
KCl, 10 mM MgCl2 and 1 mM DTT, at 25°C, 
using a SPEX-PTI spectrofluorimeter in a 1 cm 
path-length quartz cuvette, with a band-pass of 2 
nm for excitation and emission, respectively. 
Excitation was performed at 492 nm and emission 
spectra were recorded from 500 to 600 nm. 
According fluorescence experiments, a fixed 
concentration of FAM-labelled (19/36) p/t (50 nM) 
or of FITC-PAW (200 nM) was titrated with 
increasing protein concentrations from 5 nM to 1 
μM. Data were fitted as previously described 
(34,37), using a quadratic equation (GraFit, 
Erithacus Software). 
 
HPLC Size Exclusion Chromatography - 
Chromatography was performed using one 
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(Phenomenex S3000) or two HPLC columns in 
series (Phenomenex S3000 followed by 
Phenomenex S2000; both 7.5 mm x 300 mm). 
Samples containing 3 to 10 µM of RT or p51 were 
applied onto one or two HLPC columns and eluted 
with 200 mM potassium phosphate (pH: 7.0) at a 
flow rate of 0.5 ml.min-1 (5).   
 
Rapid kinetic experiments - Binding kinetics of 
p/t onto HIV-1 RT were performed with a FAM –
labelled p/t in buffer containing 50 mM Tris-HCl, 
pH 8.0, 50 mM KCl, 10 mM MgCl2 and 1 mM 
DTT, using a stopped-flow apparatus (Hi-Tech 
Scientific, Salisbury, England-UK) at 25°C. A 
fixed concentration of FAM-labeled p/t (20 nM) 
was rapidly mixed with increasing concentrations 
of RT or RT/PAW complex formed at a 1/20 molar 
ratio (25 to 400 nM). 6-FAM-fluorescence was 
excited at 492 nm and emission detected through a 
filter with a cut-off at 530 nm. Data acquisition 
and analysis were performed using KinetAsyst 3 
software (Hi-Tech Scientific, Salisbury, England-
UK) and traces were fitted according to a three 
exponential equation, as previously described (34). 
The rate constant for the first phase (k+1 and k-1), 
corresponding to the formation of a RT/PAW-p/t 
collision complex, was extrapolated from the slope 
and the intercept with the y axis of the plot of kobs1 
vs RT concentrations. The k2 (k+2 + k-2) and k3 (k+3 
+ k-3) rate constants for the second and third 
phases corresponding to conformational changes 
of preformed RT/PAW-p/t complex were directly 
obtained from the three exponential fitting.  
Dissociation kinetics of HIV-1 RT were 
monitored by using bis-ANS as extrinsic probe 
Changes in bis-ANS fluorescence provide a good 
signal to probe variation in the exposure of the 
hydrophobic regions associated to RT dissociation 
in a time-dependent manner. 0.5µM of RT was 
dissociated in presence of 0.8 µM of bis-ANS, by 
adding 10 % acetonitrile in the absence or in the 
presence of 10 µM PAW. Kinetics of dissociation 
were monitored by following fluorescence 
resonance energy transfer between tryptophan 
residues of RT and bis-ANS. Excitation of RT-Trp 
residues was performed at 290 nm and the increase 
of bis-ANS fluorescence emission at 490 nm was 
detected through a 420 nm cut-off filter. Data 
acquisition and analysis were performed using 
KinetAsyst 3 software (Hi-Tech Scientific, 
Salisbury, England-UK) and traces were fitted 
according to a single exponential equation.  
 
Cell Culture, transfection and indirect 
immunofluorescence microscopy - HeLa cells 
were cultured in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal calf serum 
at 37°C in a humidified atmosphere containing 5% 
CO2.). Cells were grown on glass coverslips to 
75% confluency, then transfected with pcDNA3-
p66RT plasmid using Lipofectamine 2000 reagent 
according to manufacturer’instructions 
(Invitrogen). For colocalization experiments, cells 
were subsequently cultured for 32h, before 
incubation with FITC-PAW or FITC-PAW/Pep-1 
(complex obtained at a molar ratio 1/10) for 1 h. 
Coverslips were extensively rinsed with PBS and 
cells were fixed in 4% paraformaldehyde for 10 
min and permeabilized in 0.2% Triton. After 
saturation in PBS supplemented with bovine serum 
albumine 1% for 1h, cells were incubated 
overnight with monoclonal 8C4 anti-HIV-1 RT 
antibody (AIDS Research Reference Reagent 
Program, NIH) (diluted 1:100 in PBS-BSA 1%), 
followed by Alexa-555 anti-mouse (Molecular 
Probes). Immunofluorescence detection of HIV-1 
RT and FITC-PAW was performed by 
epifluorescence microscopy using a PL APO 1.4 
oil PH3 objective on a LEICA DMRA 1999 
microscope. 3D reconstitution of the 20 frames 
(interval 0.3 µm) realized from z stacking was 
performed using Imaris 6.0 software.  
ATCC H9 cells, stably transfected with 
pNL4.3 V-R+ plasmid and constitutively 
expressing Gag-Pol HIV-1 proteins (obtained from 
Dr. R.Marquet-IPBS, France) were used for RT 
pull-down experiments. H9 cells were cultured in 
RPMI-1640 medium supplemented with 2mM 
glutamine, 10% (w/v) foetal calf serum (FCS), 1% 
antibiotics (streptomycin 10 000 mg/ml, penicillin, 
10 000 IU/ml) and G418 (1 mg/ml). PAW was 
incubated with 500 µl of activated CNBr-activated 
Sepharose 4B beads at 4°C overnight. After 
centrifugation, supernatants were removed and the 
beads were incubated with Glycine pH.8.0 for 2 
hrs at 4°C with gentle stirring. The beads were then 
washed with 0.1 M sodium acetate buffer (pH 4.0), 
then 0.5 M Bicarbonate buffer, and finally in PBS, 
three times each. The peptide bound to the beads 
were then saturated for 30 min in PBS/BSA 0.1% 
and then incubated for 1h at 4°C with equal 
amounts of H9 cells lysed for 30 min on ice in 
Lysis buffer (Tris 20 mM, pH 7.2, NaCl 400 mM, 
EDTA 1mM, DTT 1mM, Protease inhibitors 
EDTA free) and sonicated 2 x 5 sec. at 20%. Beads 
were washed with Lysis buffer then twice with 
PBS and the bound proteins were finally separated 
on 15% SDS-PAGE gel and analyzed by Western 
Blotting using monoclonal 8C4 anti-HIV-1 RT 
antibody.  
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Antiviral assay - The anti-HIV activities of the 
whole series of peptides were assayed according to 
previously described methods (38). 
Phytohemagglutinin-P (PHA-P)-activated 
peripheral blood mononuclear cells (PBMC) were 
infected with the reference lymphotropic HIV-1-
LAI strain (39). Virus was amplified in vitro on 
PHA-P-activated PBMC. Viral stock was titrated 
using PHA-P-activated PBMC, and 50% tissue 
culture infectious doses (TCID50) were calculated 
using Kärber’s formula (40). PBMC were pre-
treated for 1 hr with increasing concentrations of 
peptide (from 100 to 0.1 nM), then infected with 
100 TCID50 of the HIV-1-LAI strain. Peptides 
were maintained throughout the culture, and cell 
supernatants were collected at day 7 post-infection 
and stored at −20 C. Viral replication was 
measured by quantifying RT activity in cell culture 
supernatants. In parallel, cytotoxicity of the 
compounds was evaluated in uninfected PHA-P-
activated PBMC by colorimetric 3-(4-5 
dimethylthiazol-2-yl)2,5 diphenyl tetrazolium 
bromite (MTT) assay on day 7 (41). Experiments 
were performed in triplicate and repeated with 
another blood donor. Data analyses were 
performed using SoftMax®Pro 4.6 microcomputer 
software: percent of inhibition of RT activity or of 
cell viability were plotted vs concentration and 
fitted with quadratic curves; 50% effective doses 




Design and evaluation of Pep-A derived peptides 
– We have previously demonstrated that the thumb 
domain of p51 subunit is involved in activation of 
heterodimeric RT and that a 17 residue peptide, 
Pep-A, corresponding to an extremely well 
conserved structural motif located between amino 
acid “284-300”, can affect the maturation of HIV-
1 RT (22). In order to optimize and identify major 
residues in Pep-A required for RT inhibition, a 
series of new peptides have been derived from 
Pep-A sequence (RGTKALTEVIPLTEEAEC). 
First, the N-terminal arginine of Pep-A was 
removed to improve the solubility and facilitate 
the synthesis of Pep-A-derived peptides, then 
additional peptides were then generated by 
performing an alanine scan on P1. Pep-A-derived 
peptides were evaluated using a standard 
polymerase RT assay and Ki values extrapolated 
using Dixon plot analysis (36) are reported in 
Table 1.  
All peptides affected the polymerase activity of RT 
in a dose-dependent manner, and four peptides P1 
(Ki : 7.5 µM), P6 (Ki : 5.7 µM), P10 (Ki : 7.3 µM) 
and P11 (Ki : 7.0 µM) possess an inhibition 
constant lower than 10 µM (Figure 1). As a 
reference, we show that Pep-A inhibits RT-
polymerase activity with an inhibition constant 
value of 35 µM. Peptide analysis reveals that 
removing the Arg1 residue in Pep-A increases the 
potency of the peptide (P1) 5-fold. In comparison 
to P1, mutation of residues Gly1, Ala4, Glu7, and 
Leu11 into alanine significantly affects the potency 
of the peptide suggesting that the side chains of 
these residues are required for the interaction with 
RT. The nature of the side chain of Glu7 seems to 
be a major requirement for the interaction with RT 
as its substitution by Alanine (P8), reduces the 
efficiency of the peptide 8 fold. In contrast, Lys3, 
Thr6, Val8 and Glu14 residues have a minor impact 
as their mutation into alanine only reduces their 
potency by a factor of 2. Interestingly, the 
hydrophobic character of Ala4 and Val8 side chains 
plays a role in the binding of the peptide to RT and 
reducing their length affects the potency of the 
corresponding peptides to inhibit RT 2.7- and 2-
fold, respectively. Taking into account that Trp 
residues are generally involved in stabilisation of 
protein/protein interfaces, the two residues Ala4 
and Val8 were mutated into Trp, to favour the 
binding of the peptide to RT. As shown in Figure 
1, the corresponding peptide PAW significantly 
inhibits RT polymerase activity with an inhibition 
constant (Ki) of 0.7 µM, revealing that mutation of 
these two residues into Trp improves peptide 
efficiency 50-fold over Pep-A and 10-fold in 
comparison to the best lead peptide from the Ala-
scan  (P6)  (Figure 1, Table 1).  
 
Antiviral potency of Pep-A derived peptides - 
Antiviral activity of the five peptide leads (P1,P6, 
P10, P11, PAW) was evaluated on PHA-P-activated 
PBMC infected with HIV-1 LAI   Results were 
reported as 50% efficient concentration (EC50) and 
selectivity index corresponding to the ratio 
between EC50 and the cytotoxic concentration 
(CC50) inducing 50% death of uninfected PBMCs 
and relative to Pep-A and P8 (Table 2). In order to 
avoid any limitation due to the poor ability of 
peptides to cross cellular membranes, they were 
associated to the peptide-based nanoparticle 
delivery system Pep-1, at a 1/10 molar ratio. Pep-1 
has been successfully used for the delivery of 
peptides and proteins into numerous cell lines as 
well as in vivo (42,43). The inability of free 
peptides to block viral replication is directly 
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associated to their poor cellular uptake as reported 
in Figure 2A for fluorescently-labelled peptide 
(FITC-PAW). In contrast, when complexed at a 
molar 1/10 ratio with Pep-1 delivery system, 
FITC-PAW rapidly (in less than 1h) enters cells 
(Figure 2B). FITC-PAW localization and RT/PAW 
interaction were characterized using 3D 
reconstitution of frames from z stacks. 3D image 
analysis reveals that PAW does not enter the 
nucleus and partially localizes with RT at the 
periphery of the nucleus (Figures 2E & 2F).   
When associated with Pep-1, peptides P1, 
P6, P10 and P11 block viral proliferation with IC50 
values in the low µM range, which correlates with 
their ability to inhibit HIV-1 RT in vitro (Table 2). 
In contrast, in agreement with previous findings no 
antiviral activity was observed with Pep-A when 
associated to Pep-1 (22). When complexed with 
Pep-1, PAW exhibits a marked antiviral activity 
with an EC50 of 1.8 nM and a 
therapeutic/selectivity index of about 550. The 44- 
and 161-fold greater potency of PAW over peptides 
harbouring mutations at Glu7 (P8) or lacking Trp 
residues (P1) confirms the requirement of these 
residues for targeting RT both in vitro and in 
cellulo. PAW constitutes a powerful inhibitor of 
polymerase activity and possesses a very potent 
antiviral activity without any toxic effect. We 
therefore, further investigated its mechanism of 
action on RT. 
 
PAW peptide interacts with HIV-1 RT in a cellular 
context - To confirm that PAW targets HIV-1 RT in 
a cellular context, we further investigated its 
ability to form stable complexes with HIV-1 RT 
expressed in cells was investigated by pull-down 
experiments. The peptides PAW and P8 covalently 
associated with CNBr sepharose beads, was 
incubated in the presence of cell lysates of H9 
cells expressing Gag-Pol gene products of HIV-1. 
Analysis of the presence of RT by Western 
blotting reveals than only PAW was able to form 
stable complex with RT in a cellular context and to 
retain RT on beads (Figure 2G). In contrast, no RT 
was associated to free or P8-beads. 
 
Binding of PAW peptide to the dimeric form of 
HIV-1 RT.  To further understand the mechanism 
through which PAW inhibits RT, we investigated its 
potency to interact with the dimeric form of HIV-1 
RT in the absence or presence of DNA/DNA p/t. 
The binding of PAW to RT was monitored using a 
fluorescently labelled peptide (FITC-PAW). We first 
evaluated the impact of PAW labelling on the C-
terminal cysteine with an FITC-probe on its ability 
to inhibit RT polymerase activity. As reported in 
Table 1, FITC-PAW blocks RT polymerase activity 
with a Ki of 2.7 ± 0.7 µM, 3.8-fold greater than for 
PAW, suggesting that labelling has only a minor 
effect on PAW inhibitory property. As reported in 
Figure 3A, upon binding to the dimeric form of 
RT, the fluorescence of FITC-PAW was quenched 
by 39 % and analysis of the titration curves 
revealed that PAW tightly binds heterodimeric RT 
with a dissociation constant (Kd) of 33 ± 10 nM. 
When RT is first incubated with DNA/DNA p/t 
(18/36 mer), the quenching of FITC-PAW 
fluorescence associated with its binding was of 
57% and the affinity of FITC-PAW for RT increased 
5-fold (Kd : 7.1 ± 2.8 nM), suggesting that the 
presence of p/t on RT facilitates the binding of 
PAW. The association of unlabelled PAW to RT was 
also evaluated by monitoring changes in 
fluorescently labelled p/t bound to RT (Figure 3B). 
Binding of PAW results in a 39 % quenching of 
fluorescence and a Kd value of 40 ± 18 nM was 
estimated from the titration binding curve. The 5.6-
fold lower Kd of labelled FITC-PAW over 
unlabelled peptide, suggests that the dye contacts 
RT and stabilizes the peptide within its binding 
site.  
As both Trp24 and Phe61 located on the 
fingers domain of p66 subunit have been reported 
to be involved in the control of p/t binding and in 
the dynamics of the thumb-fingers subdomain 
interactions (34,44,45), we then evaluated the 
binding of PAW on RT harbouring single Phe61Gly 
and double Phe61Gly and Trp24Gly mutations on the 
p66 subunit. In comparison to wild type RT, the 
affinity of PAW  was reduced 6-fold (Kd : 207 ± 62 
nM) for p66F61G/p51wt and 4.5-fold (Kd : 149 ± 38 
nM) for p66DM/p51wt (Figure 3A).  
 
Effect of PAW peptide on primer/template binding 
to HIV-1 RT -  The impact of PAW peptide on the 
ability of HIV-1 RT to bind p/t was then 
investigated at both steady-state and pre-steady 
state levels using a 19/36 mer p/t labelled at the 3’-
end of the primer with FAM-derivative as 
previously described (34,37). As reported in Figure 
4A, the presence of a saturating concentration of 
PAW (10 µM) decreases the affinity of fluorescently 
labelled-p/t for RT 4.5-fold with a Kd value of 99 
± 40 nM in comparison to 22 ± 5 nM obtained in 
the absence of PAW. The binding of unlabeled p/t 
induces a 42 % change in the fluorescence of PAW-
FITC pre-bound to RT and leads to a similar Kd 
value of 66.5 ± 19 nM (Figure 4A). These results 
suggest that p/t interacts close to PAW binding site 
on RT, inducing a change in the orientation of 
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FITC linked to PAW, but does not share the same 
binding site.  
RT-p/t pre-steady-state binding kinetics follow 
a three-step mechanism in the presence or in the 
absence of PAW, including a rapid diffusion 
controlled second order step leading to the 
formation of the RT-p/t collision complex, 
followed by two slow, concentration-independent, 
conformational changes (34). The plot of the 
pseudo-first order rate constant for the initial 
association of the p/t with RT against RT-
concentration is linear. In the absence of PAW, k+1 
and k-1 rate constant values of 4.23⋅108 M-1⋅s-1 and 
29.9 s-1 were calculated from the slope and the 
intercept with the y axis of the graph (Figure 4B & 
4C). Analysis of the second and third slow phases 
yielded rate constants of k2 = 5.8 s-1 and k3 = 0.76 
s-1 for RT. The presence of PAW does not alter the 
overall Kd1 for the initial formation of the RT-p/t 
complex as both the “on” (k+1 = 1.05⋅108 M-1⋅s-1) 
and the “off” (k-1= 7.9 s-1) rates of the first step are 
decreased by about 4-fold. In contrast, the 
presence of PAW on RT significantly reduced the 
rate constants of the slow conformational steps (k2 
=1.99 s-1 and k3 = 0.22 s-1), affecting the proper 
binding of the p/t (Figure 4B & 4C).  
 
Effect of PAW on the stability and dimerization of 
HIV-1 RT -  The impact of PAW on the stability and 
formation of heterodimeric-RT was investigated in 
detail by size-exclusion chromatography as 
previously described (17). As reported in Figure 
5A, heterodimeric-RT incubated or not in the 
presence of an excess of PAW (100µM) for 1h30 at 
room temperature, is fully dimeric and eluted as a 
single peak at 16.7 min. The interaction of PAW 
with RT was monitored by size-exclusion 
chromatography using HIV-1 RT pre-incubated 
with FITC-PAW. Chromatography analysis reveals 
that FITC-PAW co-elutes with heterodimeric RT in 
a single peak at 16.7 min (Figure 5A), 
demonstrating that PAW binds heterodimeric RT 
and does not induce RT dissociation. We then 
evaluated the ability of PAW to interact with p66 or 
p51 monomeric forms. Experiments performed 
with a partially dissociated RT/PAW (50%) complex 
by 10% acetonitrile, show that PAW remains 
associated only with the dimeric fraction of RT, 
and does not bind monomeric p66 or p51 subunits, 
which are eluted at 17.5 min and 18.2 min, 
respectively(Figure 5B). 
We then investigated the ability of PAW to 
prevent HIV-1 RT-dimerization. Dissociation of 
RT was achieved at room temperature with 17% 
acetonitrile, and then association of the subunits 
was induced by a 10-fold dilution of the sample in 
an acetonitrile-free buffer in the absence or 
presence of 100 µM of PAW. At this concentration 
(1.7%) of acetonitrile no dissociation of RT could 
be detected. As shown in Figure 6A, heterodimeric 
RT was fully re-associated 5 hrs after dilution in an 
acetonitrile-free buffer, both in the absence or in 
the presence of PAW (100 µM), indicating that PAW 
does not block RT dimerization (Figure 6A). The 
impact of PAW was further investigated on the 
kinetics of RT-dimerization. The level of dimeric 
RT was evaluated 30 min and 2 hrs after dilution in 
free acetonitrile buffer by size-exclusion 
chromatography (Figure 6B & 6C). In the presence 
of PAW 21 % and 59 % of dimeric RT was 
quantified after 30 min and 2 hrs respectively 
(Figure 6B). In comparison only 16 % (30 min) 
and 29 % (2hrs) of dimeric RT were detected in the 
absence of peptide (Figure 6C), suggesting that the 
presence of PAW favours the kinetics of RT 
dimerization.  
 
PAW peptide favours dimerization of the small p51 
subunit -  P51 subunits are mainly monomeric and 
dissociation constants for p51/p51 homodimer 
have been reported to be either in the µM (25) or 
mM (5) range depending on the technology used to 
quantify the interactions. We have investigated the 
ability of PAW to favour p51/p51 dimerization by 
size exclusion chromatography, using two HPLC 
columns in series. Experiments were performed at 
a p51 concentration of 3.5 µM at which it is 
entirely monomeric and elutes as a single peak at 
32.7 min (Figure 7). Monomeric p51 (3.5µM) was 
incubated in the presence of FITC-labelled PAW (20 
µM) for 1 h at room temperature then analysed by 
size exclusion chromatography. As reported in 
Figure 7, in the presence of fluorescently-labelled 
PAW 4.6 % of p51 are dimeric and associated to 
PAW, suggesting that PAW promotes p51/p51 
homodimer and only p51/p51 homodimer.  
 
PAW  peptide prevents HIV-1 RT dissociation - 
Finally, the impact of PAW on HIV-1 RT  stability 
and dissociation were investigated at the steady 
state level by size exclusion chromatography and 
at the pre-steady state level by stopped-flow rapid 
kinetics. HIV-1 RT was preincubated in the 
presence of 100 µM PAW, for 2hr, prior 
dissociation with 17% or 10 % of acetonitrile, and 
the level of dimeric form was then assessed by size 
exclusion chromatography and the rate of 
dissociation by pre-steady-state kinetics. As 
reported in Fig 8A, the presence of PAW protects 
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RT from the acetonitrile dissociation as 17% 
remains dimeric whereas “free” RT is completely 
dissociated with 17% acetonitrile.  
The protection by PAW of acetonitrile-
associated RT-dissociation was further 
investigated by monitoring pre-steady-state 
dissociation kinetics of HIV-1 RT, using bis-ANS 
as an extrinsic probe (46). Binding of bis-ANS to 
dissociated RT resulted in a large increase in the 
fluorescence of the probe due to non covalent 
interactions of bis-ANS to exposed hydrophobic 
surfaces on RT subunits, therefore providing a 
good signal for following RT dissociation in a 
time-dependent manner. Experiments were 
performed by adding bis-ANS to HIV-1 RT prior 
dissociation of the enzyme by 10% acetonitrile and 
monitoring FRET between exposed Trp of RT and 
Bis-ANS. As reported in Figure 8B, the kinetics of 
increased ANS-fluorescence upon dissociation of 
RT in the absence of PAW follow a single-
exponential reaction, with a dissociation rate 
constant kdis of 5.30 ± 0.01 s-1, which is reduced 
3.8-fold (kdis =1.42 ± 0.007 s-1), when RT is 
incubated with PAW   
 
Optimization of PAW and selection of a minimal 
inhibitory peptide-motif - Taken together our 
results demonstrate that PAW constitutes a potent 
conformational inhibitor of RT and exhibits a 
potent antiviral activity. To define the minimal 
peptidic sequence for RT inhibition, new peptides 
derived from PAW were designed and evaluated 
(Table 3). As the interaction between PAW and RT 
seems to involve both the N-terminal part and Trp-
residues of the peptide, the peptidic-sequence was 
shortened at the N and/or C-terminal extremities 
and the positional effect of the Trp was evaluated. 
All peptides were tested in standard RT assays 
(Table 3) and were evaluated on PBMC infected 
by HIV-1 LAI (Table 2). Reducing PAW sequence 
by 2 residues at the N-terminus reduced efficiency 
2.5 fold (P26 : Ki= 1.8 ± 0.7 µM). In contrast, the 
5 last residues at the C-terminus of PAW can be 
removed without affecting its potency to inhibit 
RT polymerase activity or to block viral 
replication (P24 : Ki= 0.7 ± 0.05 µM and EC50 = 
2.3 nM). That P18 does not inhibit RT polymerase 
activity, confirms that the Trp residues form the 
major interface with RT. Moving Trp8 to position 
9 (P16) and both Trp4 and Trp8 to position 5 and 9 
(P17) reduced the efficiency of the corresponding 
peptides 20-fold (Ki : 14 ± 4 µM) and 50-fold (Ki : 
35 ± 11 µM), respectively. Interestingly, removing 
the last two residues of PAW increases its efficiency 
14-fold (P27 : Ki= 50 ± 0.01 nM) and is also 
associated with an increase in its antiviral activity 
with an IC50 lower than 0.32 nM and a 




Targeting the conformational flexibility of 
heterodimeric RT has provided new concepts for 
the design of drugs active on viruses resistant to 
currently used RT-inhibitors (5,17,26,28,47). RT 
activation involves a two-step dimerization process 
initiated by a rapid monomer/monomer association 
generating an inactive intermediate heterodimer, 
followed by a slow isomerization yielding the 
biologically active enzyme (5,20). Considering that 
HIV-1 RT is extremely stable (25,46,48), selection 
of compounds that are able to dissociate the 
complex remains challenging. In contrast, as 
maturation of RT requires less energy than 
dimerization, targeting conformational changes 
involved is a very attractive approach for the 
design of novel antiviral compounds. Maturation 
of the inactive intermediate heterodimer 
corresponds to conformational changes involving 
interactions between the thumb of p51 and the 
RNAse H of p66 and between the fingers of p51 
and the palm of p66 (20). We previously 
demonstrated that the thumb domain of p51 plays a 
major role in RT-maturation and that a synthetic 
peptide (Pep-A) derived from this domain 
selectively inhibited activation of HIV-1 RT (22). 
In the present work, we report the design of a new 
generation of peptide inhibitors derived from the 
thumb domain and have identified a lead peptide 
PAW that efficiently blocks both maturation of RT 
and viral replication. 
 
PAW peptide preferentially binds dimeric RT in the 
“open” conformation - From size exclusion 
chromatography, we clearly demonstrated that PAW 
only binds dimeric forms of RT (p66/p51 and 
p51/p51). Moreover, as already reported for Pep-A 
(22), PAW does not induce heterodimer dissociation 
nor prevent the monomer/monomer association, 
and instead significantly increases stability of the 
heterodimer and favours dimerization. According 
to the two step process mechanism, we propose 
that PAW blocks RT maturation by stabilizing the 
inactive intermediate of RT in a non processive 
conformation. 
Determination of crystal structures of the 
HIV-1 RT associated or not with a p/t has revealed 
that the binding of p/t to RT triggers major 
conformational changes in the overall structure of 
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the enzyme, including the increase in the 
compactness together with conversion of RT from 
a “closed” to an “open” conformation (7-9). The 
structure RT adopts two conformational states: a 
“closed” conformation stabilized by interactions 
between fingers and thumb domains of p66 and an 
“open” conformation associated with a change in 
the orientation of the thumb domain and a shift of 
the fingers domain which are induced by p/t 
binding (8,9). We demonstrate that PAW tightly 
binds RT preferentially in the “open” 
conformation, as its affinity is increased 5-fold in 
the presence of p/t. The dynamics of the thumb 
and fingers domains of p66 and the conformational 
changes of RT associated with p/t binding exposes 
the binding site of PAW, was strengthened by the 
fact that mutation of Phe61 into glycine on the 
fingers domain of p66 subunit altered binding of 
PAW to RT (6-fold).  Phe61 is located in the fingers 
domain and together with Trp24 and Arg78 is 
involved in the stabilization of the “closed” 
conformation of RT, by contacting the loop 
between helices αI and αJ of the thumb domain. 
Given that mutation of Phe61 favours the “open” 
conformation of RT (34), but dramatically reduces 
the affinity of PAW for RT, suggests that this 
residue is directly involved in the binding of PAW. 
And that PAW binding site is located close to this 
residue on either the thumb or fingers domain of 
p66. 
 
PAW peptide blocks RT in an inactive 
conformation altering proper binding of 
primer/template - The initial monomer/monomer 
interaction yields an intermediate dimer lacking of 
polymerase and RNAse H activities, then 
corrected organisation of the catalytic and the p/t 
binding sites occurs during a slow maturation step 
(20). We propose that PAW interacts directly with 
the intermediate inactive form which stabilizes in a 
non-processive conformation. From a mechanistic 
point of view, PAW acts as non-competitive 
inhibitor affecting conformational changes 
required for proper folding of the p/t binding site. 
PAW does not displace RT:p/t complex but reduces 
both “off” and “on” rates of the collisional binding 
of p/t to RT, it does not affected the overall 
dissociation constants of the collisonal step, with 
K1 values of 70.4 nM and 70.6 nM obtained in the 
presence or the absence of PAW, respectively. In 
contrast, PAW dramatically affects the proper 
binding and conformational changes that place 
correctly the p/t for catalysis. The corresponding 
rate constants are reduced by 3-fold (k2) and 3.4 
fold (k3), respectively. Taken together that PAW 
binds heterodimeric and homodimeric RTs 
(p66/p51 and p51/p51), preferentially in the 
“open” conformation, and that it specifically 
inhibits polymerase activity and not RNAse H, 
demonstrates that PAW interacts with the inactive 
intermediate form of RT and prevents 
conformational changes required for the proper 
folding of the p/t binding site.  
Similarly, NNRTIs are non competitive 
inhibitors that block RT in a non processive 
conformation (24-28). NNRTIs bind near the RT-
polymerase catalytic site and affect the dynamics 
of thumb/finger domain interaction on p66 subunit 
and maintain RT in an “open” conformation 
(6,8,10). Although the molecular mechanism by 
which NNRTIs inhibit RT is not entirely clear, 
evidence reports that binding of NNRTIs restricts 
the mobility of the thumb domain, slowing or 
preventing p/t translocation and thereby inhibiting 
elongation of nascent DNA. NNRTIs such as 
efavirenz favour RT dimerization in vitro and in 
cultured cells (24), but in contrast to PAW, they 
improve the binding of p/t (35,50), which excludes 
that PAW and NNRTI binding sites overlap and 
favours a PAW binding site close to the interface 
between the thumb and fingers domain of p66.  
 
PAW is potent antiviral compound - When 
associated with Pep-1-based nanoparticles, PAW is 
a potent non toxic inhibitor of viral replication 
(EC50: 1.8 nM). This peptide constitutes a major 
improvement in comparison to Pep-A which is 50-
fold less potent in vitro on RT activity and does not 
exhibit any antiviral activity in the same delivery 
conditions. We demonstrate that when delivered 
into cells using Pep-1, PAW interacts with RT in 
both cells expressing only p66 and in the context 
of the full Pol-polyprotein. Taking together this 
result with the fact that PAW EC50 values on HIV-
LAI are similar to its dissociation constant for RT, 
confirms that PAW inhibition occurs via 
conformational changes on RT and not through 
direct inhibition of polymerase activity. The 
analysis of PAW sequence has revealed that 
essential residues involved in RT binding and 
antiviral activity are located in the N-terminus of 
the peptide. In particular, Glu7, Leu11, Trp4 and 
Trp8 are required for binding of PAW to RT. The 
hydrophobic character of the side chain of Trp-
residues at position 4 and 8 plays a major role in 
stabilizing PAW/RT complex. We show that PAW 
can be reduced to 12 residues (P24) without 
affecting either its in vitro or in cellulo potency. 
Interestingly, removing the last two residues of 
PAW (P27) increases in vitro and antiviral 
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efficiency 12-fold and 10-fold, respectively. These 
results suggest that although the Trp residues are 
key residues for the potency of the peptide, 
residues 12 to 14 in the sequence of PAW are also 
required to stabilize PAW in its binding site. 
 
Conclusions - In the present work, we have 
demonstrated that the dynamics of the 
finger/thumb domains of p66 play an essential role 
in the stabilisation and maturation of 
heterodimeric HIV-1 RT. As such, we have 
established a proof of concept that targeting 
conformational changes required for RT flexibility 
can lead to highly potent antiviral molecules. We 
have identified a new RT inhibitor, PAW which 
alters finger/thumb dynamics and maintains RT in 
a non-processive conformation, by altering the 
proper binding of p/t to RT. Development of this 
type of inhibitor together with a better knowledge 
of its mechanism at the viral level will provide new 
perspectives for designing specific inhibitors of the 
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Figure 1: Inhibition of the HIV-1 RT polymerase activity by Pep-A derived peptides. HIV-1 RT 
(40 nM) was incubated with increasing concentrations of Pep-A-derived peptides, P1 (●), P6 (), P10 
(■), P11 (▼) and PAW (▲), then polymerase reaction was initiated by addition of a mix containing 
poly(rA).(dT)15 and dTTP substrates. Inhibition constants were extrapolated from Dixon plots (36).  
 
Figure 2: HIV-1 RT interacts with PAW in cultured cells. (A-F) cellular localization of PAW and its 
interaction with HIV-1 RT in cellulo was monitored using HeLa cells expressing RT transfected with 
FITC-PAW/Pep-1 complex formed at a 1/10 molar ratio. HIV-1 RT (Alexa 555 secondary antibody) 
and FITC-PAW were respectively visualized through a Cy3 and a GFP filter. HeLa cells transfected 
with free FITC-PAW (A) or complexed with Pep-1 (B). Cultured Hela cells transfected (D) with 
pcDNA3-p66RT. HeLa cells co-transfected with both pcDNA-p66RT and FITC-PAW/Pep-1 at a 1/10 
molar ratio. The RT/PAW co-localisation was analyzed by the 3-D image reconstitution with Imaris 6.0 
software of 20 frames from z stacks (E,F). RT, PAW and nuclear staining with Hoechst are reported in 
red, green and blue, respectively. Global view (D), 3D image analysis of a selected cell (red arrow) 
reveals that PAW and RT localize in the cytoplasm at the periphery of the nucleus. (F) Zoom of the box 
reported in panel E. (G) Interaction between PAW and HIV-1 RT detected in a CNBr-pull-down assay. 
Experiments were performed as described in Materials and Methods. 30 µg (total protein) per lane 
were separated on 15% SDS-PAGE and subjected to Western blotting using rabbit anti-RT antibody. 
Lanes correspond to control free beads, P8-, PAW-beads and total proteins loaded on the gel, 
respectively. 
 
Figure 3: Binding titration of FITC-PAW to RT and RT-p/t. (A) Titration of FITC-PAW binding to 
RT (○), RT:p/t (●), p51wt/p66F61G (U) or p51wt/p66DM (). A fixed 200 nM concentration of FITC-
PAW was titrated with increasing concentrations of HIV-1 RTs or RT:p/t. The binding of PAW to RT 
was monitored by following the quenching of extrinsic PAW fluorescence at 512 nm, upon excitation at 
492 nm. (B) Titration of PAW binding to RT:FAM-p/t. A fixed 20 nM concentration of RT:p/t was 
titrated with increasing concentrations of PAW. The binding of PAW to RT was monitored by following 
the quenching of extrinsic fluorescence of FAM-labelled p/t at 512 nm, upon excitation at 492 nm.  
Kd values were calculated using a quadratic equation and correspond to the mean of at least three 
separate experiments. 
 
Figure 4: Impact PAW peptide on the binding of primer/template to HIV-1 RT. (A) Titration of 
fluorescently labelled p/t binding to RT (○) or RT/PAW (●) and of FITC-PAW/RT binding to p/t (▲). A 
fixed 50 nM concentration of fluorescently-labelled p/t was titrated with increasing concentrations of 
RT or RT/PAW. The binding of p/t to RT was monitored by following the quenching of p/t extrinsic 
fluorescence at 512 nm, upon excitation at 492 nm. A fixed 100 nM concentration of FITC-PAW/RT 
complex was titrated by increasing concentrations of p/t (18/36). The binding of FITC-PAW/RT to p/t 
was monitored by following the quenching of PAW extrinsic fluorescence at 512 nm, upon excitation at 
492 nm. Kd values were calculated using a quadratic equation as previously described (20) and 
correspond to the mean of at least three separate experiments. Kinetics of binding of fluorescently 
labelled p/t to RT (B) and RT/PAW (C). Typical stopped-flow time courses are reported, where a fixed 
20 nM concentration of FAM-labelled p/t was rapidly mixed with 100 nM of RT (B) or RT/PAW (C). 
Data collection acquisition and analysis were performed using KintAsyst 3 software and kinetics were 
fitted using a three exponential equation. (D) Secondary plot of the dependence of the fitted pseudo-
first order rate constants for the first phase on RT (○) or RT/PAW (●) concentration.  
 
Figure 5: Binding of PAW to heterodimeric RT as monitored by size-exclusion chromatography.  
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(A) Heterodimeric RT (2.3 µM) was incubated in the presence of PAW (10 µM) for 1h30 at room 
temperature, then applied onto a gel filtration column and eluted with 200 mM potassium phosphate 
buffer, pH 7.0. (B) Heterodimeric RT (10 µM) was incubated in the presence of FITC-PAW (150 µM) 
for 2h at room temperature then partially dissociated by 10% acetonitrile for 30 min and analyzed by 
gel filtration. Proteins were monitored at 280 nm (blue line) and fluorescein-labelled peptide at 492 
nm (orange line). 
 
Figure 6: Effect of PAW peptide on HIV-1 RT-dimerization.  (A) Impact of PAW on RT-
dimerization. 10 µM of RT was dissociated in the presence of 17% acetonitrile yielding 2 peaks 
corresponding to p66 and p51 subunits (in black), then p51 and p66 subunits were diluted in an 
acetonitrile free buffer and incubated overnight at room temperature in the absence (in blue) or 
presence of 100 µM PAW (in red). Kinetics of subunit dimerization 30 min (B) and 2 hrs (C) after 
dilution in an acetonitrile free buffer. 10 µM of fully dissociated RT were incubated in the presence 
(in red) or absence of 100 µM PAW (in blue), then dimerization was induced by dilution in an 
acetonitrile free buffer and the level of dimer/monomers was monitored at 30 min and 2 hrs by size 
exclusion chromatography.  
 
Figure 7 : PAW peptide favours dimerization of the small p51 subunit. HIV-1 p51 (3.5 µM) free 
(in blue) or incubated with FITC-PAW (20 µM) (in red) were applied onto a size exclusion 
chromatography using two HPLC columns in series. Proteins were monitored at 280 nm and 
fluorescein-labelled PAW at 492 nm (in orange).   
 
Figure 8: PAW peptide prevents HIV-1 RT dissociation. (A) PAW associated protection of RT from 
the acetonitrile dissociation as monitored by size exclusion chromatography. First, HIV-1 RT (8.7 
µM) was incubated in the presence (red line) or absence (blue line) of fluorescently labelled PAW (100 
µM) then dissociated by 17% acetonitrile for 30 min at room temperature and applied onto a size 
exclusion chromatography. (B) Kinetics of RT dissociation induced by acetonitrile. RT (0.5 µM) was 
dissociated in the presence of 0.8 µM bis-ANS, by adding 10 % acetonitrile in the absence (blue line) 
or presence of 5 µM PAW (red line). The kinetics of dissociation were monitored by following the 
fluorescence resonance energy transfer between tryptophan of RT and Bis-ANS. Tryptophan 
excitation was performed at 290 nm and the increase of bis-ANS fluorescence emission at 490 nm 
was detected through a 420 nm cut-off filter. Data acquisition and analysis were performed using 
KinetAsyst 3 software (Hi-Tech Scientific, Salisbury, England-UK) and traces were fitted according 
to a single exponential equation.  
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 Peptides Sequences Ki (µM) a 
 
 PepA RGTKALTEVIPLTEEAEC  35± 5 
 P1 GTKALTEVIPLTEEAEC 7.5± 2.3 
 P2 ATKALTEVIPLTEEAEC 28± 11 
 P3 GAKALTEVIPLTEEAEC 10.3± 2.1 
 P4 GTAALTEVIPLTEEAEC 15± 2.9 
 P5 GTKGLTEVIPLTEEAEC 20± 3.7 
  P6 GTKAATEVIPLTEEAEC 5.7±  2.3 
 P7 GTKALAEVIPLTEEAEC 13.5± 2.1 
 P8 GTKALTAVIPLTEEAEC 57± 19 
 P9 GTKALTEAIPLTEEAEC 15± 7.3 
 P10 GTKALTEVAPLTEEAEC 7.3± 2.9 
 P11 GTKALTEVIALTEEAEC 7± 1.4 
 P12 GTKALTEVIPATEEAEC 22± 3 
 P13 GTKALTEVIPLAEEAEC 10.2± 2.5 
 P14 GTKALTEVIPLTAEAEC  14± 3 
 P15 GTKALTEVIPLTEAAEC 14± 2.2 
 Pscramble GAKTETLVIPETELEAC 61 ± 12 
 PAW GTKWLTEWIPLTAEAEC 0.7± 0.2 
 PAW-FITC GTKWLTEWIPLTAEAEC-FITC 2.7 ± 0.7 
 
 
a. RT polymerase activity was measured as described in the Materials and Methods. The inhibition 
constants Ki were calculated from Dixon plots and reported data correspond to the mean of three 
separate experiments.  
  




Table  2: Antiviral activity of Pep-A and PAW-derived peptides  
 
 
 Peptides EC50 (nM) a SI b 
 
 P1/Pep-1 78.2 >ND 
 P6/Pep-1 170 > 3 
 P8/Pep-1 290 > 3 
 P10/Pep-1 140 ND 
 PAW  > 1000 ND 
 PAW/Pep-1 1.8 > 550 
 P18/Pep-1 >1000 ND 
 P24/Pep-1 2.3 > 1200 
 P26/Pep-1 >1000 ND 
 P27 > 1000 ND 
 P27/Pep-1 < 0.32 > 3100 
 
 
a. anti-HIV activity was evaluated on PHA-P-activated PBMC infected with HIV-1-LAI strain. EC50 
values correspond to the 50% effective peptide dose  
b. Selectivity index, which corresponds to the ratio between EC50 and the cytotoxic concentration 
(CC50) inducing 50% death of uninfected PBMCs 
ND: value not determined 
  




Table 3 : PAW-derived peptide sequences and Inhibition of polymerase activity of HIV-1 RT.  
 
 
a. RT polymerase activity was measured as described in the Materials and Methods. The inhibition 
constants Ki were calculated from Dixon plots and reported data correspond to the mean of three 




Peptides Sequences Ki(µM) a 
 
 
PAW GTKWLTEWIPLTAEAEC 0.7± 0.2 
P16 GTKWLTEVWPLC 14± 4 
P17 GTKAWTEVWPLC 35± 11 
P18 GTKALTEVIPLTC 53± 12 
P19 GTKAATEVIPLTC 49± 9 
P24 GTKWLTEWIPLC 0.7± 0.05 
P26      KWLTEWIPLTAEAEC 1.8± 0.7 
P27 GTKWLTEWIPLTAEC 0.05± 0.01 
P28 GTKWATEWAPLTAEAEC 2± 0.6  
P29      KWLTEWIPLTAEC 1± 0.4 
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Figure 3  
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Figure 4   
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